B-[4-(1-甲基乙基)-5-嘧啶]-硼酸 | 913835-27-5

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: B-[4-(1-甲基乙基)-5-嘧啶]-硼酸
• 中文别名: 4-异丙基嘧啶-5-硼酸
• 英文名称: (4-isopropylpyrimidin-5-yl)boronic acid
• 英文别名: 4-Isopropylpyrimidine-5-boronic acid；(4-propan-2-ylpyrimidin-5-yl)boronic acid
• CAS: 913835-27-5
• 化学式: C₇H₁₁BN₂O₂
• mdl: MFCD08235084
• 分子量: 165.988
• InChiKey: SMZXLPHORPDPKW-UHFFFAOYSA-N

物化性质

• 熔点：
  104-109
• 沸点：
  337.7±44.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.87
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Isopropylpyrimidine-5-boronic acid
Product Name:
Synonyms: 4-Isopropyl-5-pyrimidineboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Isopropylpyrimidine-5-boronic acid
Ingredient name:
CAS number: 913835-27-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H11BN2O2
Molecular weight: 166.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-4-氟苯酚 、 B-[4-(1-甲基乙基)-5-嘧啶]-硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 20.0h， 以300 mg的产率得到4-fluoro-2-(4-isopropylpyrimidin-5-yl)phenol
  参考文献：
  名称：

  [EN] INHIBITORS OF THE MENIN-MLL INTERACTION
  [FR] INHIBITEURS DE L'INTERACTION MÉNINE-MLL

  摘要：

  本发明涉及抑制menin与MLL及MLL融合蛋白相互作用的抑制剂，包含这些抑制剂的药物组合物，以及它们在治疗由menin-MLL相互作用介导的癌症和其他疾病中的应用。

  公开号：

  WO2017214367A1

文献信息

• CYCLOALKANE-1,3-DIAMINE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20210269454A1

  公开（公告）日：2021-09-02

  The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Ring Q 1 , W, m and n are each as defined in the description.

  本发明提供了一种具有对menin和MLL蛋白相互作用抑制作用的化合物或其药学上可接受的盐。该化合物由式（1）表示，或其药学上可接受的盐。 在式（1）中，虚线圈，R1，R2，R3，R4，R5，R6，R7，R8，环Q1，W，m和n的定义如描述中所述。
• Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS
  作者：Timothy R. Hodges、Jason R. Abbott、Andrew J. Little、Dhruba Sarkar、James M. Salovich、Jennifer E. Howes、Denis T. Akan、Jiqing Sai、Allison L. Arnold、Carrie Browning、Michael C. Burns、Tammy Sobolik、Qi Sun、Yugandhar Beesetty、Jesse A. Coker、Dirk Scharn、Heinz Stadtmueller、Olivia W. Rossanese、Jason Phan、Alex G. Waterson、Darryl B. McConnell、Stephen W. Fesik

  DOI：10.1021/acs.jmedchem.8b01108

  日期：2018.10.11

  Son of sevenless homologue 1 (SOS1) is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS. In its active form, GTP-bound RAS is responsible for numerous critical cellular processes. Aberrant RAS activity is involved in ∼30% of all human cancers; hence, SOS1 is an attractive therapeutic target for its role in modulating RAS activation. Here, we describe a new series

  七分之一同源基因1（SOS1）的儿子是鸟嘌呤核苷酸交换因子，它催化RAS上的GTP交换GDP。GTP结合的RAS以其活跃的形式负责众多关键的细胞过程。约30％的人类癌症都涉及RAS异常活动。因此，SOS1因其在调节RAS激活中的作用而成为有吸引力的治疗靶标。在这里，我们描述了一系列新的苯并咪唑衍生的SOS1激动剂。使用结构指导的设计，我们发现了小分子，可在亚微摩尔浓度下增加RAS在体外的核苷酸交换，以低的两位数纳摩尔亲和力与SOS1结合，迅速增强细胞RAS-GTP水平，并在ERK磷酸化中引起双相信号变化。 1/2。这些化合物代表了迄今为止报道的最有效的SOS1激动剂系列。
• [EN] PYRIDINE OR PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDINE OU DE PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017072083A1

  公开（公告）日：2017-05-04

  The present invention relates to compounds of formula (I), wherein R1' is methyl; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R3 is CI, F, CF3, methyl, methoxy, or cyclopropyl; R4 is hydrogen, methyl, F or CI; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer. The compounds of formula (I) may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

  本发明涉及式(I)的化合物，其中R1'为甲基；R1为甲基、乙基、三氟甲基、羟甲基、环丙基或氰基，或R1'和R1可共同形成1,1-二氧代四氢噻吩-3-基环；R2为氢、甲基、乙基、异丙基、叔丁基、环丙基、环丙基甲基或羟甲基；R3为氯、氟、三氟甲基、甲基、甲氧基或环丙基；R4为氢、甲基、氟或氯；X为N或CH；Y为N或CH；但X和Y不同时为CH；或其药学上可接受的盐或酸加盐，或其外消旋混合物，或其对应的对映体和/或光学异构体和/或立体异构体。式(I)的化合物可用于治疗精神障碍，如精神分裂症、躁郁症、强迫症或自闭症谱系障碍。
• [EN] BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA<br/>[FR] COMPOSÉS BICYCLIQUES UTILISÉS COMME MODULATEURS DE ROR-GAMMA
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015035032A1

  公开（公告）日：2015-03-12

  The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

  本发明涵盖了式(I)的化合物：其中变量如本文所定义，适用于调节RORC并治疗与调节RORC相关的疾病。本发明还涵盖了制备式(I)化合物的过程以及含有它们的药物制剂。
• [EN] AZAINDOLE COMPOUNDS AS MODULATORS OF RORC<br/>[FR] COMPOSÉS D'AZAINDOLE À TITRE DE MODULATEURS DE RORC
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015017335A1

  公开（公告）日：2015-02-05

  The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

  本发明涵盖了式（I）的化合物，其中变量在此处定义，适用于调节RORC并治疗与RORC调节相关的疾病。本发明还涵盖了制备式（I）化合物的方法以及含有它们的药物制剂。